A prospective subgroup analysis of two prospective, randomized, double-blind, placebo-controlled phase III clinical trials showed that the combination of lenalidomide plus dexamethasone is superior to dexamethasone alone in patients with relapsed or refractory multiple myeloma who had been previously treated with thalidomide; the implications for clinical practice are discussed.

Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Clinical Trials, Dexamethasone, Dose-Response Relationship, Double-Blind Method, Drug, Follow-Up Studies, Humans, Multiple Myeloma, Phase III as Topic, Prospective Studies, Randomized Controlled Trials as Topic, Recurrence, Survival Rate, Thalidomide, Time Factors, Treatment Outcome, adjuvant chemotherapy, antineoplastic agent, dexamethasone, dose response, double blind procedure, drug derivative, follow up, human, lenalidomide, mortality, multiple myeloma, note, phase 3 clinical trial, prospective study, randomized controlled trial, recurrent disease, survival rate, thalidomide, time, treatment outcome
dx.doi.org/10.1038/nrclinonc.2009.50, hdl.handle.net/1765/16739
Nature Reviews Clinical Oncology
Erasmus MC: University Medical Center Rotterdam

Meijer, E, & Sonneveld, P. (2009). Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. Nature Reviews Clinical Oncology, 6(5), 247–248. doi:10.1038/nrclinonc.2009.50